These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30992063)

  • 1. Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion.
    Spataro R; Kousi M; Farhan SMK; Willer JR; Ross JP; Dion PA; Rouleau GA; Daly MJ; Neale BM; La Bella V; Katsanis N
    Hum Genomics; 2019 Apr; 13(1):19. PubMed ID: 30992063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).
    Estrada-Cuzcano A; Martin S; Chamova T; Synofzik M; Timmann D; Holemans T; Andreeva A; Reichbauer J; De Rycke R; Chang DI; van Veen S; Samuel J; Schöls L; Pöppel T; Mollerup Sørensen D; Asselbergh B; Klein C; Zuchner S; Jordanova A; Vangheluwe P; Tournev I; Schüle R
    Brain; 2017 Feb; 140(2):287-305. PubMed ID: 28137957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.
    Bras J; Verloes A; Schneider SA; Mole SE; Guerreiro RJ
    Hum Mol Genet; 2012 Jun; 21(12):2646-50. PubMed ID: 22388936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
    Park JS; Sue CM
    Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.
    Pietrzak A; Badura-Stronka M; Kangas-Kontio T; Felczak P; Kozubski W; Latos-Bielenska A; Wierzba-Bobrowicz T; Florczak-Wyspianska J
    Folia Neuropathol; 2019; 57(3):285-294. PubMed ID: 31588715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP13A2 missense variant in Australian Cattle Dogs with late onset neuronal ceroid lipofuscinosis.
    Schmutz I; Jagannathan V; Bartenschlager F; Stein VM; Gruber AD; Leeb T; Katz ML
    Mol Genet Metab; 2019 May; 127(1):95-106. PubMed ID: 30956123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations.
    Erro R; Picillo M; Manara R; Pellecchia MT; Barone P
    Parkinsonism Relat Disord; 2019 Aug; 65():272-273. PubMed ID: 31151786
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.
    Yang X; Xu Y
    Biomed Res Int; 2014; 2014():371256. PubMed ID: 25197640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype correlation in seven motor neuron disease families with novel ALS2 mutations.
    Sprute R; Jergas H; Ölmez A; Alawbathani S; Karasoy H; Dafsari HS; Becker K; Daimagüler HS; Nürnberg P; Muntoni F; Topaloglu H; Uyanik G; Cirak S
    Am J Med Genet A; 2021 Feb; 185(2):344-354. PubMed ID: 33155358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
    Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
    Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.
    Chiò A; Borghero G; Restagno G; Mora G; Drepper C; Traynor BJ; Sendtner M; Brunetti M; Ossola I; Calvo A; Pugliatti M; Sotgiu MA; Murru MR; Marrosu MG; Marrosu F; Marinou K; Mandrioli J; Sola P; Caponnetto C; Mancardi G; Mandich P; La Bella V; Spataro R; Conte A; Monsurrò MR; Tedeschi G; Pisano F; Bartolomei I; Salvi F; Lauria Pinter G; Simone I; Logroscino G; Gambardella A; Quattrone A; Lunetta C; Volanti P; Zollino M; Penco S; Battistini S; ; Renton AE; Majounie E; Abramzon Y; Conforti FL; Giannini F; Corbo M; Sabatelli M
    Brain; 2012 Mar; 135(Pt 3):784-93. PubMed ID: 22366794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.
    Schultheis PJ; Fleming SM; Clippinger AK; Lewis J; Tsunemi T; Giasson B; Dickson DW; Mazzulli JR; Bardgett ME; Haik KL; Ekhator O; Chava AK; Howard J; Gannon M; Hoffman E; Chen Y; Prasad V; Linn SC; Tamargo RJ; Westbroek W; Sidransky E; Krainc D; Shull GE
    Hum Mol Genet; 2013 May; 22(10):2067-82. PubMed ID: 23393156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel ATP13A2 variant causing complicated hereditary spastic paraplegia.
    Zhang F; Liu P; Li J; Cen Z; Luo W
    Neurol Sci; 2024 Apr; 45(4):1749-1753. PubMed ID: 38252374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Parkinson-associated human P5B-ATPase ATP13A2 modifies lipid homeostasis.
    Marcos AL; Corradi GR; Mazzitelli LR; Casali CI; Fernández Tome MDC; Adamo HP; de Tezanos Pinto F
    Biochim Biophys Acta Biomembr; 2019 Oct; 1861(10):182993. PubMed ID: 31132336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.
    Di Fonzo A; Chien HF; Socal M; Giraudo S; Tassorelli C; Iliceto G; Fabbrini G; Marconi R; Fincati E; Abbruzzese G; Marini P; Squitieri F; Horstink MW; Montagna P; Libera AD; Stocchi F; Goldwurm S; Ferreira JJ; Meco G; Martignoni E; Lopiano L; Jardim LB; Oostra BA; Barbosa ER; ; Bonifati V
    Neurology; 2007 May; 68(19):1557-62. PubMed ID: 17485642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERLIN1 mutations cause teenage-onset slowly progressive ALS in a large Turkish pedigree.
    Tunca C; Akçimen F; Coşkun C; Gündoğdu-Eken A; Kocoglu C; Çevik B; Bekircan-Kurt CE; Tan E; Başak AN
    Eur J Hum Genet; 2018 May; 26(5):745-748. PubMed ID: 29453415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability.
    Santoro L; Breedveld GJ; Manganelli F; Iodice R; Pisciotta C; Nolano M; Punzo F; Quarantelli M; Pappatà S; Di Fonzo A; Oostra BA; Bonifati V
    Neurogenetics; 2011 Feb; 12(1):33-9. PubMed ID: 20853184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia.
    Yan J; Deng HX; Siddique N; Fecto F; Chen W; Yang Y; Liu E; Donkervoort S; Zheng JG; Shi Y; Ahmeti KB; Brooks B; Engel WK; Siddique T
    Neurology; 2010 Aug; 75(9):807-14. PubMed ID: 20668259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation.
    Inzelberg R; Estrada-Cuzcano A; Laitman Y; De Vriendt E; Friedman E; Jordanova A
    J Parkinsons Dis; 2018; 8(3):399-403. PubMed ID: 29966207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
    Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
    Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.